To quantify muscle relaxation properties of fingerflexors using transcranial magnetic stimulation in patients with different myopathies to develop a screening diagnostic tool to assess who does (not) suffer from an underlying myopathy.
ID
Source
Brief title
Condition
- Musculoskeletal and connective tissue disorders congenital
- Muscle disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Peak relaxation rate normalized for force
Relaxation times: 0.9RT, 0.75RT, 0.50RT, 0.25RT
E.g. 0.50RT is the time needed for force to drop from 100% to 50% of maximal
force
Secondary outcome
Maximal force of fingerflexors
Background summary
Transcranial magnetic stimulation can induce involuntary muscle relaxation by
interrupting corticospinal drive to the muscle (~200ms). Previous research
using this method has demonstrated that patients with Brody disease had
significantly slower muscle relaxation as compared to healthy controls. We want
to study if slowed muscle relaxation is also seen in other myopathies with
positive muscle phenomena (muscle cramp, stiffness and myalgia) and possibly
also in myopathies with mainly negative muscle phenomena (atrophy, weakness).
Study objective
To quantify muscle relaxation properties of fingerflexors using transcranial
magnetic stimulation in patients with different myopathies to develop a
screening diagnostic tool to assess who does (not) suffer from an underlying
myopathy.
Study design
Experimental research to dermine muscle relaxation properties using
transcranial magentic stimulation in different myopathies compared to healthy
controls with comparable complaints (positive muscle phenomena, without an
underlying myopathy).
Study burden and risks
One visit to our lab of 45 minutes. There will be slight discomfort from the
TMS (mild headache in 2-4% of subjects).
Reinier Postlaan 4
Nijmegen 6525 GC
NL
Reinier Postlaan 4
Nijmegen 6525 GC
NL
Listed location countries
Age
Inclusion criteria
Diagnosis of one of the following myopathies:
- Nemaline myopathy type 6 (NEM6)
- Ryanodine receptor type 1 related myopathy (RYR1)
- Myotonic dystrophy type 2 (DM2)
- Mitochondrial myopathy
- McArdle disease
- Facioscapulohumeral muscular dystrophy (FSHD)
Exclusion criteria
Age <18
Pregnancy
Serious head trauma or brain surgery
Large or ferromagnetic metal parts in the head
Implanted cardiac pacemaker or neurostimulator
Epilepsy, convulsion or seizure
Use of medication that can influence muscle relaxation or cortical excitability
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL57301.091.16 |